Immunotherapy Options for Breast Cancer
Trial results raise questions about two immune checkpoint inhibitors approved for treatment of some people with advanced breast cancer.
Progress Against Cancer
Trial results raise questions about two immune checkpoint inhibitors approved for treatment of some people with advanced breast cancer.
Fecal transplants may improve immunotherapy responses, and more news of the week from Cancer Today.
Increasing representation in the biomedical workforce would have many benefits, including reducing implicit biases and cultural incompetency in the treatment of minority patients with cancer, as well as ensuring the inclusion of diverse perspectives and enhancing innovation and creativity in cancer research.
The AACR is proud to support World Cancer Day, an annual initiative led by the International Union for Cancer Control.
The FDA approved the combination of an immune checkpoint inhibitor and a therapeutic that prevents tumors from growing blood vessels to treat certain patients with renal cell carcinoma. The U.S. Food and Drug Administration...
Advocates are asking that cancer patients be prioritized for COVID-19 vaccination, and more news of the week from Cancer Today.
The FDA approved a molecularly targeted therapeutic for treating certain patients with some rare cancers affecting the gastrointestinal system. The U.S. Food and Drug Administration (FDA) has approved the molecularly targeted therapeutic fam-trastuzumab deruxtecan-nxki (Enhertu) to treat adult...
African American men are more likely to feel regret about prostate cancer treatment decisions, and more news of the week from Cancer Today.
The FDA approved a molecularly targeted therapeutic to treat certain pediatric patients and young adults with anaplastic large-cell lymphoma, a rare form of non-Hodgkin lymphoma.
People are using crowdsourced fundraising to cover cancer care costs, and more news of the week from Cancer Today.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More